Your browser doesn't support javascript.
loading
Recommendations for risk allele evidence curation, classification, and reporting from the ClinGen Low Penetrance/Risk Allele Working Group.
Schmidt, Ryan J; Steeves, Marcie; Bayrak-Toydemir, Pinar; Benson, Katherine A; Coe, Bradley P; Conlin, Laura K; Ganapathi, Mythily; Garcia, John; Gollob, Michael H; Jobanputra, Vaidehi; Luo, Minjie; Ma, Deqiong; Maston, Glenn; McGoldrick, Kelly; Palculict, T Blake; Pesaran, Tina; Pollin, Toni I; Qian, Emily; Rehm, Heidi L; Riggs, Erin R; Schilit, Samantha L P; Sergouniotis, Panagiotis I; Tvrdik, Tatiana; Watkins, Nicholas; Zec, Lauren; Zhang, Wenying; Lebo, Matthew S.
Affiliation
  • Schmidt RJ; Children's Hospital Los Angeles, Keck School of Medicine of USC, Los Angeles, CA. Electronic address: rschmidt@chla.usc.edu.
  • Steeves M; Color Health, Burlingame, CA.
  • Bayrak-Toydemir P; Department of Pathology, University of Utah Molecular Genetics and Genomics, ARUP Laboratories, Salt Lake City, UT.
  • Benson KA; School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Ireland.
  • Coe BP; Department of Pathology & Lab Medicine, BC Children's & BC Women's Hospitals, Vancouver, Canada.
  • Conlin LK; Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA; Division of Genomic Diagnostics, Children's Hospital of Philadelphia, Philadelphia, PA.
  • Ganapathi M; Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY.
  • Garcia J; Invitae, San Francisco, CA.
  • Gollob MH; Inherited Arrhythmia and Cardiomyopathy Program, Division of Cardiology, Toronto General Hospital and Department of Physiology, University of Toronto, Toronto, Ontario, Canada.
  • Jobanputra V; New York Genome Center, New York, NY; Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY.
  • Luo M; Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA; Division of Genomic Diagnostics, Children's Hospital of Philadelphia, Philadelphia, PA.
  • Ma D; DNA diagnostic lab, Department of Genetics, School of Medicine, Yale University, New Haven, CT.
  • Maston G; Quest Diagnostics, Inc., Hillsboro, OR.
  • McGoldrick K; Ambry Genetics, Aliso Viejo, CA.
  • Palculict TB; GeneDx, Gaithersburg, MD.
  • Pesaran T; Ambry Genetics, Aliso Viejo, CA.
  • Pollin TI; University of Maryland School of Medicine, Baltimore, MD.
  • Qian E; Department of Genetics, Yale University School of Medicine, New Haven, CT.
  • Rehm HL; Center for Genomics Medicine, Massachusetts General Hospital, Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA.
  • Riggs ER; Geisinger Autism & Developmental Medicine Institute, Lewisburg, PA.
  • Schilit SLP; Mass General Brigham, Brigham and Woman's Hospital, Harvard Medical School, Boston, MA.
  • Sergouniotis PI; Division of Evolution, Infection and Genomics, University of Manchester, Manchester, United Kingdom.
  • Tvrdik T; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA.
  • Watkins N; Department of Pathology and Laboratory Medicine, Sinai Health System, Toronto, Ontario, Canada Department of Molecular Genetics, University of Toronto, Toronto, Canada.
  • Zec L; Natera, Inc., Austin, TX.
  • Zhang W; Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH.
  • Lebo MS; Mass General Brigham, Brigham and Woman's Hospital, Harvard Medical School, Broad Institute of MIT and Harvard, Cambridge, MA. Electronic address: mlebo@bwh.harvard.edu.
Genet Med ; 26(3): 101036, 2024 Mar.
Article in En | MEDLINE | ID: mdl-38054408
ABSTRACT

PURPOSE:

Genetic variants at the low end of the penetrance spectrum have historically been challenging to interpret because their high population frequencies exceed the disease prevalence of the associated condition, leading to a lack of clear segregation between the variant and disease. There is currently substantial variation in the classification of these variants, and no formal classification framework has been widely adopted. The Clinical Genome Resource Low Penetrance/Risk Allele Working Group was formed to address these challenges and promote harmonization within the clinical community.

METHODS:

The work presented here is the product of internal and community Likert-scaled surveys in combination with expert consensus within the Working Group.

RESULTS:

We formally recognize risk alleles and low-penetrance variants as distinct variant classes from those causing highly penetrant disease that require special considerations regarding their clinical classification and reporting. First, we provide a preferred terminology for these variants. Second, we focus on risk alleles and detail considerations for reviewing relevant studies and present a framework for the classification these variants. Finally, we discuss considerations for clinical reporting of risk alleles.

CONCLUSION:

These recommendations support harmonized interpretation, classification, and reporting of variants at the low end of the penetrance spectrum.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Genetic Variation Limits: Humans Language: En Journal: Genet Med Journal subject: GENETICA MEDICA Year: 2024 Type: Article

Full text: 1 Database: MEDLINE Main subject: Genetic Variation Limits: Humans Language: En Journal: Genet Med Journal subject: GENETICA MEDICA Year: 2024 Type: Article